Nine-Year-Old Becomes Third Patient Worldwide to Receive Experimental Gene Therapy for Rare Batten Disease
核心洞察
Jack Timmerman, a 9-year-old from South Carolina with CLN-1 Batten Disease (搜索), will become the third person globally to receive an experimental gene replacement therapy (搜索) at Rush Hospital (搜索) in Chicago.
The rare neurological disorder affects only 1 in 250,000 live births and has caused Jack to lose 90-95% of his eyesight due to a mutated gene preventing enzyme production.
The experimental treatment, led by Dr. Elizabeth Berry-Kravis, aims to replace the defective gene to enable natural enzyme production and halt disease progression.
A 9-year-old boy from South Carolina is set to become only the third person worldwide to receive an experimental gene replacement therapy (搜索) for a rare and fatal neurological condition. Jack Timmerman will travel to Rush Hospital (搜索) in Chicago on August 25 to undergo the groundbreaking treatment for CLN-1 Batten Disease (搜索), a condition affecting just 1 in 250,000 live births.
Rare Disease Diagnosis After Months of Medical Journey
Jack's medical journey began when he was around six years old, as his parents Ned and Jaime Timmerman noticed changes in his eyesight. "He was having a harder time locating things, seeing things, he was feeling for more things, and that led us on a medical journey," said Ned Timmerman.
The diagnosis took over eight months and consultations with several doctors before Jack was identified as having Batten Disease (搜索), specifically the CLN-1 variant. According to the Batten Disease Support, Research, & Advocacy (BDSRA) Foundation, there are 14 variants of this rare neurological disorder that attacks the nervous system.
The condition stems from a mutated gene that prevents Jack from producing an enzyme responsible for eliminating waste from his brain and central nervous system. This genetic defect has resulted in Jack losing 90-95% of his eyesight and learning to navigate life using braille.
Experimental Treatment Offers New Hope
With no cure currently available for Batten Disease (搜索), the Timmerman family focused on supporting Jack through his condition. However, they eventually learned about an experimental drug that had been offered to only two other patients worldwide.
Dr. Elizabeth Berry-Kravis, who is spearheading the experimental treatment, evaluated Jack as a candidate for the therapy. "She was the one that said, 'I think he is a good candidate for an experimental treatment, we've only done it twice, it's very special,' and it's going to stop it from getting worse. It's not a cure, but it's hopefully an opportunity to put a pin in where we are," said Ned Timmerman.
Gene Replacement Mechanism
The experimental drug was not originally designed to treat Batten Disease (搜索) but has shown promise in the two previous cases. The treatment is intended to replace the defective gene, enabling Jack to start producing the necessary enzyme himself.
"It changes everything, I feel like just the hope that this provides will give us more time for science to catch up even more, and then there could be more possibilities for more treatment, maybe eyesight, who knows. This, I feel like, will buy us more time, and that to me, that's just so encouraging," said Jaime Timmerman.
Treatment Timeline and Community Support
Jack will remain in Chicago for several weeks following the treatment for follow-up appointments before returning home. The family has organized community support through a "Jack Attack Friends Forever Tour" event to help cover treatment expenses, demonstrating the broader impact of rare disease research on families and communities.